ORCA
Online Research @ CardiffÂ
Browse by Current Cardiff authors
![[up]](/style/images/multi_up.png)
Up a levelNumber of items: 2.
Russell, Nigel H., Wilhelm-Benartzi, Charlotte  ORCID: https://orcid.org/0000-0003-4927-6158, Knapper, Steve ORCID: https://orcid.org/0000-0002-6405-4441, Batten, Leona M., Canham, Joanna ORCID: https://orcid.org/0000-0003-3482-0990, Hinson, Emily L., Overgaard, Ulrik Malthe, Gilkes, Amanda, Othman, Jad, Potter, Nicola, Dillon, Richard, Mehta, Priyanka, Kottaridis, Panagiotis, Cavenagh, Jamie, Hemmaway, Claire, Arnold, Claire, Freeman, Sylvie D and Dennis, Mike
2022.
FLAG-Ida combined with Gemtuzumab Ozogamicin (GO) improves event free survival in younger patients with newly diagnosed Acute Myeloid Leukaemia (AML) and shows an overall survival benefit in NPM1 and FLT3 mutated subgroups. Results from the UK NCRI AML19 trial.
Blood
140
(S1)
, pp. 526-528.
10.1182/blood-2022-162377
|
|
|
Othman, Jad, Dillon, Richard, Wilhelm-Benartzi, Charlotte ORCID: https://orcid.org/0000-0003-4927-6158, Knapper, Steve ORCID: https://orcid.org/0000-0002-6405-4441, Batten, Leona M, Canham, Joanna ORCID: https://orcid.org/0000-0003-3482-0990, Hinson, Emily L., Villiers, William, Kleeman, Michelle, Gilkes, Amanda, Potter, Nicola, Overgaard, Ulrik Malthe, Mehta, Priyanka, Kottaridis, Panos, Cavenagh, Jamie, Hemmaway, Claire, Arnold, Claire, Dennis, Mike and Russell, Nigel H.
2022.
Genomic correlates of outcome in a randomised comparison of CPX-351 and FLAG-Ida in high-risk acute myeloid leukaemia and myelodysplastic syndrome: results from the UK NCRI AML19 Trial.
Presented at: 64th ASH Annual Meeting and Exposition,
New Orleans, Louisiana,
10-13 December 2022.
Blood.
, vol.140
(S1)
American Society of Hematology,
pp. 1036-1038.
10.1182/blood-2022-159433
|
|
|
Cardiff University Information Services